Cenix to Use Definiens' Cellenger System | GenomeWeb
NEW YORK (GenomeWeb News) – RNAi research services company Definiens said today that Cenix BioScience has expanded a license agreement to continue to use Definiens’ data extraction technology in its microscopy assays for high throughput RNAi studies in human and rodent cells.
 
Under the agreement, Cenix will integrate the Definiens Cellenger system into its existing high-throughput and high-content RNAi-based research infrastructure, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.